Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pro-glucagon (Homo sapiens (Human)) | BDBM2437 (US8507533, 157) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 5.55 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100827 (US8507533, 138 | US8507533, 151 | US8507533, 374) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 5.75 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100806 (US8507533, 114 | US8507533, 115 | US8507533, 330) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 7.60 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Atypical chemokine receptor 3 (Homo sapiens (Human)) | BDBM50264278 (CHEMBL4064803) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | Article PubMed | 9 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description Binding affinity to CXCR7 (unknown origin) assessed as inhibition constant | Citation and Details Article DOI: 10.1016/j.bmcl.2021.128320 BindingDB Entry DOI: 10.7270/Q2Q2441F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2390 (US8507533, 146) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 9.05 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Glucagon receptor (Homo sapiens (Human)) | BDBM50433595 (CHEMBL2381827) | PDB MMDB UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | CHEMBL PC cid PC sid UniChem Similars | Article PubMed | 12 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. Curated by ChEMBL | Assay Description Displacement of [125I]-glucagon-cex from human glucagon receptor by cell based assay in presence of 0.2% bovine serum albumin | Bioorg Med Chem Lett 23: 3051-8 (2013) Article DOI: 10.1016/j.bmcl.2013.03.014 BindingDB Entry DOI: 10.7270/Q27M099R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Glucagon receptor (Homo sapiens (Human)) | BDBM50433577 (CHEMBL2381848) | PDB MMDB UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | Purchase CHEMBL MCE PC cid PC sid UniChem Similars | Article PubMed | 14 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. Curated by ChEMBL | Assay Description Displacement of [125I]-glucagon-cex from human glucagon receptor by cell based assay in presence of 0.2% bovine serum albumin | Bioorg Med Chem Lett 23: 3051-8 (2013) Article DOI: 10.1016/j.bmcl.2013.03.014 BindingDB Entry DOI: 10.7270/Q27M099R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100806 (US8507533, 114 | US8507533, 115 | US8507533, 330) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 15.8 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100796 (US8507533, 101) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 17 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Atypical chemokine receptor 3 (Homo sapiens (Human)) | BDBM50567153 (CHEMBL4855707) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | Article PubMed | 17 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description Binding affinity to CXCR7 (unknown origin) assessed as inhibition constant | Citation and Details Article DOI: 10.1016/j.bmcl.2021.128320 BindingDB Entry DOI: 10.7270/Q2Q2441F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100827 (US8507533, 138 | US8507533, 151 | US8507533, 374) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 20.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2376 (US8507533, 137) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 20.2 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100844 (US8507533, 160 | US8507533, 398) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 25.7 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2391 (US8507533, 147) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 26.7 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100850 (US8507533, 168) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 27.4 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100852 (US8507533, 170 | US8507533, 419) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 28 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100844 (US8507533, 160 | US8507533, 398) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 29 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100822 (US8507533, 129 | US8507533, 162 | US8507533, 399) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 29.3 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2241 (US8507533, 136) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 30.2 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100838 (US8507533, 153) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 32.3 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2240 (US8507533, 135) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 35 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100837 (US8507533, 152) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 35.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100805 (US8507533, 113) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 38.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Atypical chemokine receptor 3 (Homo sapiens (Human)) | BDBM50567152 (CHEMBL4877999) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | Article PubMed | 40 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description Binding affinity to CXCR7 (unknown origin) assessed as inhibition constant | Citation and Details Article DOI: 10.1016/j.bmcl.2021.128320 BindingDB Entry DOI: 10.7270/Q2Q2441F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2438 (US8507533, 158) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 41 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100861 (US8507533, 188) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | Purchase PC cid PC sid PDB UniChem Similars | US Patent | 42.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100864 (US8507533, 193) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 44.7 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100815 (US8507533, 122) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 45.7 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Atypical chemokine receptor 3 (Homo sapiens (Human)) | BDBM50264279 (CHEMBL4072602) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | Article PubMed | 47 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description Binding affinity to CXCR7 (unknown origin) assessed as inhibition constant | Citation and Details Article DOI: 10.1016/j.bmcl.2021.128320 BindingDB Entry DOI: 10.7270/Q2Q2441F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100822 (US8507533, 129 | US8507533, 162 | US8507533, 399) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 47.3 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2229 (US8507533, 187 | US8507533, 448) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 47.8 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100824 (US8507533, 131) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 51 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Atypical chemokine receptor 3 (Homo sapiens (Human)) | BDBM50567151 (CHEMBL4848754) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | Article PubMed | 52 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description Binding affinity to CXCR7 (unknown origin) assessed as inhibition constant | Citation and Details Article DOI: 10.1016/j.bmcl.2021.128320 BindingDB Entry DOI: 10.7270/Q2Q2441F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Atypical chemokine receptor 3 (Homo sapiens (Human)) | BDBM50567148 (CHEMBL4875191) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | Article PubMed | 53 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description Binding affinity to CXCR7 (unknown origin) assessed as inhibition constant | Citation and Details Article DOI: 10.1016/j.bmcl.2021.128320 BindingDB Entry DOI: 10.7270/Q2Q2441F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100801 (US8507533, 109 | US8507533, 322) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 57.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2387 (US8507533, 143) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 57.4 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100826 (US8507533, 133) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 58 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100831 (US8507533, 144) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 62.6 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100829 (US8507533, 140) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 62.8 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Glucagon receptor (Homo sapiens (Human)) | BDBM50433576 (CHEMBL2381849) | PDB MMDB UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | Purchase CHEMBL PC cid PC sid UniChem Similars | Article PubMed | 64 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. Curated by ChEMBL | Assay Description Displacement of [125I]-glucagon-cex from human glucagon receptor by cell based assay in presence of 0.2% bovine serum albumin | Bioorg Med Chem Lett 23: 3051-8 (2013) Article DOI: 10.1016/j.bmcl.2013.03.014 BindingDB Entry DOI: 10.7270/Q27M099R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100847 (US8507533, 163) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 65.9 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100797 (US8507533, 105) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 69.8 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100799 (US8507533, 107) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 71.6 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100856 (US8507533, 181) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 87.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100816 (US8507533, 123) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 88.4 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100830 (US8507533, 141) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 89.5 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100798 (US8507533, 106) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 91.9 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100794 (US8507533, 300 | US8507533, 97 | US8507533, 98) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 93 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100823 (US8507533, 130 | US8507533, 369) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 93.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2408 (US8507533, 155) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 94.9 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 987 total ) | Next | Last >> |